https://webnewsinsider.com/fda-issues-draft-guidance-to-accelerate-approval-of-individualized-gene-editing-therapies/ WebNewsInsider en 2026-10-28T05:22:06+08:00 FDA Issues Draft Guidance to Accelerate Approval of Individualized Gene Editing Therapies https://webnewsinsider.com/gsk-doubles-cancer-drug-trials-to-navigate-patent-cliff-and-rebuild-oncology-portfolio/ WebNewsInsider en 2026-10-27T13:11:28+08:00 GSK Doubles Cancer Drug Trials to Navigate Patent Cliff and Rebuild Oncology Portfolio https://webnewsinsider.com/understanding-medical-debt-protections-and-hospital-billing/ WebNewsInsider en 2026-10-27T09:11:14+08:00 Understanding Medical Debt Protections and Hospital Billing https://webnewsinsider.com/legal-battles-over-cancer-funding-delay-life-saving-care-for-patients/ WebNewsInsider en 2026-10-26T20:16:12+08:00 Legal Battles Over Cancer Funding Delay Life-Saving Care for Patients https://webnewsinsider.com/how-private-credit-facilities-expand-access-to-affordable-consumer-lending/ WebNewsInsider en 2026-10-26T19:27:34+08:00 How Private Credit Facilities Expand Access to Affordable Consumer Lending https://webnewsinsider.com/stanford-digital-twins-identify-drug-combo-to-stop-premature-birth/ WebNewsInsider en 2026-10-26T18:42:03+08:00 Stanford Digital Twins Identify Drug Combo To Stop Premature Birth https://webnewsinsider.com/why-microsatellite-instability-status-dictates-rectal-cancer-treatment-choices/ WebNewsInsider en 2026-10-26T17:43:30+08:00 Why Microsatellite Instability Status Dictates Rectal Cancer Treatment Choices https://webnewsinsider.com/why-kras-was-considered-undruggable-for-decades-and-what-finally-cracked-it/ WebNewsInsider en 2026-10-26T16:16:38+08:00 Why KRAS Was Considered Undruggable for Decades and What Finally Cracked It https://webnewsinsider.com/first-human-data-show-er-100-gene-therapy-well-tolerated-in-glaucoma-trial/ WebNewsInsider en 2026-10-26T10:27:15+08:00 First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed https://webnewsinsider.com/interpath-001-trial-shows-intismeran-cuts-melanoma-recurrence-risk-42/ WebNewsInsider en 2026-10-26T09:07:24+08:00 INTerpath-001 trial shows intismeran cuts melanoma recurrence risk 42%